BAX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for alleged violations of federal securities laws related to the Novum LVP device malfunctions, which posed serious risks to patients [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Baxter securities between February 23, 2023, and July 30, 2025 [2]. - Allegations include that Baxter misled investors by failing to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, exposing patients to serious injury or death [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the devices from service [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Baxter have until December 15, 2025, to request to be appointed as lead plaintiff in the case [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].